Late toxicity after whole pelvic irradiation in prostate cancer patients irradiation

Abstract

Author(s): Ahmed Sabah Mohammed Jamil, Hayder Hamza Alabedi, Imad Khalid Ahmed

Objectives: The study aimed to evaluate late toxicity after whole pelvic irradiation in prostate cancer patients.

Methods: A cross-sectional study of 15 non-metastatic prostatic cancer patients treated with radiotherapy were included. The analysis was conducted at Baghdad Radiotherapy and Nuclear Medicine Center, Baghdad Medical City Complex, Baghdad, Iraq, between December 2022 and May 2022. Data were collected retrospectively with the review of medical records. The following variables were studied: age, residency (address), smoking habits, TNM staging, histopathology, grades, GS, initial PSA concentration, ADT, treatment modality, the dose of RT, risk group, adverse effects including diarrhoea, pain, dysuria, anaemia, retention, haematuria, lymphedema, incontinence,urgency and sexual dysfunction, PTV95%, and OAR constraints doses.

Results: The mean age of patients was 68.47 ± 8.15 years, with a median age of 65 and most patients above 60 years. Most of the patients were smokers, 14 (93.3%). Most patients have a history of comorbid condition 14 (93.3%). All prostatic cancer cases in this study were adenocarcinoma. Stage I recorded in 3 (20%) patients, stage III in 6 (40%), and stage IV in 6 (40%). Regarding the Gleason score, the median GS in this study was 7. The mean of PSA was 39.09 ± 38.74 ng/mL (median=23 ng/mL). Yet, no retention, anaemia, hematuria, or lymphedema was recorded. Approximately the percentage of adverse effects was 26.7% diarrhoea, 26.7% pain, 6.7% BPR, 20% dysuria, 6.7% incontinence, 13.4% urgency, and 60% sexual dysfunction.

Conclusions: To the best of our knowledge, this is the first study in Iraq to evaluate late toxicity after whole pelvic irradiation in prostate cancer patients.

Share this article